Skip Navigation LinksPerformance-Trends-for-US-CA-Objectives

Top Menu

TUBERCULOSIS CONTROL BRANCH

California Tuberculosis Performance Trends with California Targets and United States Performance​

Most Recent Five Years of Data Available, 2018-2022, 2019-2023, and 2020-2024

​Strategy 1: Diagnosis and Treatment of Persons with TB Disease

Objective​​

​2018

​2019

​2020

​2021

​2022

​2023

​2024

​CA Target *

​​US Average **

​1.1a TB Case Rate (per 100,000 population)

​—

​—

​4.3

​4.5

​4.7

​5.4

​5.4

​3.9

​3.1

​1.1b US-Born Case Rate​​

​—

​—

​0.9

​1.1

​1.1

​1.3

​1.2

​1.0

​0.8

​1.1c Non US-Born Case Rate

​—

​—

​13.5

​13.6

​14.7

​16.4

​16.4

​11.6

16.8 ##

​1.1d African American Case Rate

​​—

​​—

​2.1

​1.7

​2.1

​2.4

​1.9

​2.1 #

​​2.2 ##

​1.1e Pediatric Case Rate

​​—

​​—​

​1.0

​1.1

​1.2

​1.3

​1.2

​0.9

​1.5 ##

​1.1f Asian Case Rate ***

​​—

​​—

15.3​

​14.7

​15.3

16.7​

​16.2

​14.3

​NA

​1.1g Hispanic/Latinx Case Rate ***

​​—

​​—

​3.9

​4.5

​4.8

​5.4

​5.7

​3.5

​NA

​1.1h White Case Rate ***

​​—

​​—

​0.8

​0.7

​0.7

​1.0

​0.8

​0.6

​NA

​1.2 Known HIV Status (%)

​​—

​​—

​91

​90

​91

​93

​90

​94

​90 ##

​1.3 Laboratory Turnaround Time – Culture (%)

​—

​—

​55

​53

​48

​44

​36

​72

​45

​1.4 Laboratory Turnaround Time – NAAT (%)

​—​

​​—​

​90

​90

​85

​74

​75

​96

​79

​1.5 Drug Susceptibility Result (%)

​​—

​​—

​98

​96

​97

​96

​95

​99

​92 ##

​1.6 Sputum Culture Reported (%)

​​—

​​—

​94

​95

​96

​94

​93

​98

​94

​1.7 Recommended Initial Therapy (%)

​​—

​​—

​89

​92

​92

​92

​91

​95

​92

​​1.8 Treatment Initiation (%)

​​—​

​​—​​

​86

​85

​84

​88

​87

​98

​86 ##

​1.9 Sputum Culture Conversion (%)

​73

​74

​74

​71

​69

​—

​—

​75

​​69 ##

​1.10 Completion of Treatment (%)

​​88

​​89

90​

86​

85​

—​

​​—​

91​

87​

​1.11a Nucleic Acid Amplification Test Used - Smear-Positive TB (%) ***

​​—

​​—

​76

78​

71​

64​

64​

81​

NA​

​1.11b Nucleic Acid Amplification Test Used - Smear-Negative TB (%) ***

​​—

​​—

​43

43​

46​

​41

46​

​50

​NA

​1.12 Self-Administered Therapy (%) ***

​2.1

​2.3

​2.1

​1.4

​0.9

​—

​—

1.9 #​

​NA

​1.13 Deaths With TB (%) ***

​10.1

​11.5

​13.4

​12.4

​14.0

​—

​—​

​6.7

​NA​

Strategy 2A: Contact Investigation of Infectious TB Cases

​Objective
​2018
​2019
​2020
​2021
​2022
​2023
​2024
​CA Target *
​US Average **
​2A.1 Contact Elicitation (%)
​—
​91
​91
​92
​88
​89
​—
​97
​87 ##
​2A.2 Contact Examination (%)
​—
​74
​82
​82
​78
​77
​—
​91
​70 ##
​2A.3 Contact LTBI Treatment Initiation (%)
​—​
​66
​75
​78
​71
​68
​—
76​​76
​2A.4 Contact LTBI Treatment Completion (%)
​—
​69
​74
​74
​73
​68
​—​
​84
​​77

​​Strategy 2B: Examination and Treatment of Immigrants and Refugees with Class B1 Notification

​Objective

​2018
​2019
​2020
​2021
​2022
​2023
​2024
​CA Target *
​US Average **
2B.1 Immigrant/Refugee Evaluation Initiation within 30 Days (%)​​—
​—
​26
​25
​18
​19
​18
​69
​31
​2B.2 Immigrant/Refugee Evaluation Completion within 120 Days (%)

​—
​—
​57
​38
​28
​29
​31
​65
​40
​2B.3 Immigrant/Refugee Evaluation Complete (%) ***

​—
​—
​57
​61
​​57
​56
​49
​77
​NA
2B.4 Immigrant/Refugee LTBI Treatment Initiation (%)
—​​65
​71
​62
​65
​58
​—
​75
​61
​2B.5 Immigrant/Refugee LTBI Treatment Completion (%)
​—
​71
​85
​68
​79
​71
​—
​70 #
​​74
​2B.6 Data Reporting - EDN (%)​
​—
​74
​70
​72
​71
​67
​—
​82
​74

Strategy 4: Epidemiologic Surveillance and Response

​Objective
​2018
​2019
​2020
​2021
​2022
​2023
​2024
​CA Target *
​US Average **
​​​4.1. Data Reporting - RVCT (%)
​99
99​​99
​98
​98
​—
​—​
​99
​99
​4.2 Universal Genotyping (%)
​—
​—
​98
​98
​97
​97
​97
​99
​​96 ##


* Target shown is for latest year of performance, and is marked with # if latest complete year of data meets or exceeds the target.​

** for most current full year of data shown for California; marked with ## if California performance equals or exceeds US performance

*** California (non-NTIP) indicators 

Case rates shown are form the National TB Indicators Project (NTIP) reports accessed August 2025, using 2024 frozen dataset. These rates may differ from those shown in other California-produced reports due to data sources used for population denominators.

Table abbreviations: TB = tuberculosis, US = United States, HIV = human immunodeficiency virus, RVCT = Report of Verified Case of TB, LTBI = latent TB infection, ARPE-CI = Aggregate Report of Performance Evaluation – Contact Investigation, NA = data not available or applicable

California Department of Public Health – Tuberculosis Control Branch                                      updated April 2025

​​​
Page Last Updated :